Not a healthcare professional? Visit our Public site
logo
Therapy Areas

Oestrogel® (estradiol 0.06% w/w)

Empower her to manage her menopause
product-image
Utrogestan Product Packshot
Menopause Product Packshot
oestrogel logo
image_7_a811017b73.png

Oestrogel® (estradiol 0.06% w/w) is a convenient,* body-identical, transdermal oestrogen gel for everyday use2,3

*Based on UK market research conducted by Besin’s Healthcare (UK) Ltd. 41% (n=66) of patients switched to Oestrogel stated that Oestrogel has a convenient dosing regimen which fits their lifestyle.

INDICATIONS3

Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women.       

Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.       

The experience treating women older than 65 years is limited.  
For treating postmenopausal symptoms, the lowest effective dose should be used for the shortest duration, with HRT initiated only when symptoms significantly impact quality of life.      

The lowest effective dose for the prevention of osteoporosis is not known.

A preferred treatment choice2

Icon 1
Number 1 prescribed transdermal oestrogen in the UK†1
†NHS prescription data from April 2024 to March 20251
item_3_0db8c38cb5_772db79049.png
An easy-to-use,† clear colourless gel containing 17β-estradiol2,3
item_2_4b56590999_493aa6501c.png
Convenient dosing regime to fit with patient’s lifestyle‡2,3
‡Based on market research conducted by Besin’s Healthcare (UK) Ltd. 41% (n=66) of patients switched to Oestrogel stated that Oestrogel has a convenient dosing regimen which fits their lifestyle. 85% (n=78) of surveyed patients who switched from other treatments preferred Oestrogel. Easy-to-use, based on market research conducted by Besins Healthcare (UK) Ltd. 95% (n=156) of Oestrogel patients are very/fairly satisfied with the ease of use of their pump pack.2
item_4_8fd542fa62_d7e54c6392.png
No sticky adhesive3
improved_check_a52889d701_a450e44b20.png
As effective as oestrogen patches at relieving vasomotor symptoms (gel 95% [n=25] vs patch 100% [n=28])§4

§Statistical analysis in a prospective randomised comparative trial in India, wherein participants allocated oral, gel or patch was performed using multiple analysis of variants and chi-square tests wherever appropriate, with p value ≤0.05 considered significant. Results of percutaneous gel vs transdermal patch p>0.05, non-significant. Gel 95% (n=25) vs patch 100% (n=28).Statistical analysis was performed using multiple analysis of variants and chi-square tests wherever appropriate, with p-values of ≤0.05 considered significant. Results of percutaneous gel vs transdermal patch p>0.05, non-significant.4

The number of patients showing skin intolerance at first month was significantly higher among the reservoir patch group: (92%) n=12 compared to only (22%) n=3 in the matrix patch group and (10%) n=3 among the gel group.4

High satisfaction with Oestrogel

88% of users are "satisfied" or "extremely satisfied" with Oestrogel

An observational survey evaluated patient outcomes with 0.06% estradiol gel found that 88% (n=890) of users reported being either "satisfied" (n=383) or "extremely satisfied (n=400)”.#5

#This was an observational study conducted between 2009 and 2010, in which menopausal patients prescribed estradiol gel 0.06% (N=2,485) enrolled in a web-based patient portal which monitored patient outcomes to track outcomes, with assessments conducted at baseline (pre-treatment) and during therapy. Measures included hot flash frequency and severity, vaginal dryness severity, onset of efficacy, ease of use, satisfaction and product preference. Estradiol gel 0.06% initiation may have occurred after the baseline assessment or up to 12 or more months prior to the baseline outcomes assessment.

Group_82_1_ec05979915.png

Proven to reduce hot flushes6

Oestrogel significantly reduces the mean daily frequency of moderate to severe hot flushes at Week 12 compared to placebo (p<0.05).6

 Study design (Archer 2003)6
 A 12-week, multicentre, double-blind, randomised, placebo-controlled study of the effects of Oestrogel in 221 postmenopausal women to assess the effects of a percutaneous 17β-estradiol gel on vasomotor symptoms (VMS) compared to placebo.

 Inclusion criteria6
 Participants were assigned to receive either 1.25g or 2.5g of percutaneous 17β-estradiol gel or placebo, applied once daily over a 12-week period to evaluate efficacy and tolerability.

 Primary endpoint6
 The mean change from baseline to Week 12 in the daily frequency of moderate-to-severe hot flushes.

 Secondary endpoint6
 Frequency and severity of all VMS and vaginal maturation index.

 Safety and tolerability assessments were based on:6
 

  • Adverse events (>10%) reported in a 221-patient placebo-controlled trial in postmenopausal women over a 12-week period.
  • The most common adverse events were headache(18.1%), breast pain(10.4%), infection(10.0%), pain(7.7%), nausea(7.2%), rash(5.4%), and vaginitis(5.4%)

Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis3

  • Oestrogel is the only HRT gel pump pack indicated for prevention of osteoporosis in postmenopausal women, women who are at high risk of future fractures, women who are intolerant to, or with a contraindication to, other osteoporosis preventive medications3,7
  • Around 40% of all postmenopausal women will eventually experience fractures (seen in a longitudinal study in the USA, N=1,902)8

 Simple dosing that can be tailored3   
 
  • Pump-pack enables dose tailoring from 2 to 4 pump actuations per day.3

Dosing for menopausal and postmenopausal symptoms2

Dose (pump actuations)Amount of OestrogelEstradiol contentUsage notes
1 pump1.25 g0.75 mgEach metered dose
2 pumps2.5 g1.5 mgUsual starting dose which the majority of women will provide effective relief of symptoms
3 pumps3.75 g2.25 mgConsider if 2 pumps do not relieve symptoms after 1 month
4 pumps5 g3.0 mgMaximum recommended daily dose
AMOUNT OF OESTROGEL
1 pump1.25 g
2 pumps2.5 g
3 pumps3.75 g
4 pumps5 g
ESTRADIOL CONTENT
1 pump0.75 mg
2 pumps1.5 mg
3 pumps2.25 mg
4 pumps3.0 mg
USAGE NOTES
1 pumpEach metered dose
2 pumpsUsual starting dose which the majority of women will provide effective relief of symptoms
3 pumpsConsider if 2 pumps do not relieve symptoms after 1 month
4 pumpsMaximum recommended daily dose

For initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used.3

  • This medicine contains 0.5g alcohol (ethanol) in each dose of 1.25g gel3
  • Do not apply to damaged skin3
  • This product is flammable until dry3
  • Patients should be informed that children should not come in contact with the area of the body where Oestrogel was applied on due to the transfer risk. Post-marketing reports of breast development and sexual changes following unintentional secondary exposure have been reported. In most cases, the condition resolved with removal of estradiol exposure.3
  • For the treatment of postmenopausal symptoms, HRT should only be initiated for symptoms that adversely affect quality of life. In all cases, a careful appraisal of the risks and benefits should be undertaken at least annually, and HRT should only be continued as long as the benefit outweighs the risk3

Please refer to the Summary of Product Characteristics for more information on adverse effects including risk of venous thromboembolism, breast cancer and stroke. HRT should only be continued as long as the benefit outweighs the risk.3

Support your patients on how to apply Oestrogel

Set up your Oestrogel Pump-Pack

For first use – setting up the pump pack 11

Step 1

Step 1 illustration

Conical bottle A. Remove the cap.

Cylindrical bottle B. Remove the cap and then release the stopper without breaking it's tether to the bottle – you will need to replace the stopper on the nozzle after each use.

1/3

How to apply

Make sure you know how many doses (pump actuations) you should use. Your doctor will have provided this information to you.

Step 1

Step 1 illustration

Before applying, make sure that your hands and the skin you are treating are clean, dry and free from any cuts or abrasions.

1/7

A tailored dosing schedule3

Does your patient have a uterus?

dosing_schedule_401b3f325f (1).png

Consider transdermal Oestrogel for your eligible postmenopausal patients for VMS control and Utrogestan® (micronised progesterone) 100mg to greatly reduce the oestrogen-induced risk of endometrial hyperplasia in non-hysterectomised women.3,6,10,12

Menopause guidelines information →
Book a meeting with a representative →

Abbreviations

HRT, hormone replacement therapy; TEAE, treatment-emergent adverse event; VMS, vasomotor symptoms.

References

  1. Data on file. REF-OES-00473 July 2025
  2. Data on file. REF-OES-00454 May 2025
  3. Oestrogel (estradiol) Pump-Pack 750 micrograms/actuation gel Summary of Product Characteristics.
    https://www.medicines.org.uk/emc/product/353/smpc.Accessed August 2026
  4. Akhila V, Pratapkumar. Int J Fertil 2006;51(2):64–9.
  5. Simon JA, et al. SRM 2011; October supplement.
  6. Archer DF, et al. Menopause 2003;10(6):516–521.
  7. Sandrena Summary of Product Characteristics.
    https://www.medicines.org.uk/emc/product/1048/smpcAccessed August 2026
  8. Finkelstein JS, et al. J Clin Endocrinol Metab. 2008;93(3):861–8.
  9. Palacios S, et al. Maturitas 1994;20(2):209–13.
  10. Fournier A, et al. Am J Epidemiol 2014;180(5):508–517.
  11. Utrogestan 100mg (micronised progesterone) Summary of Product Characteristics.
    https://www.medicines.org.uk/emc/product/352/smpcAccessed August 2026
August 2026 | MAT-PROMO-OES-0308

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: drugsafety@besins-healthcare.com

Back to top
Footer logo